Cargando…

High glucose promotes hepatic fibrosis via miR-32/MTA3-mediated epithelial-to-mesenchymal transition

Hepatic fibrosis is characterized by the aberrant production and deposition of extracellular matrix (ECM) proteins. Growing evidence indicates that the epithelial-mesenchymal transition serves a crucial role in the progression of liver fibrogenesis. Although a subset of microRNAs (miRNAs or miRs) ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qiang, Li, Zhange, Lin, Yuan, Che, Hui, Hu, Yingying, Kang, Xujuan, Zhang, Ying, Wang, Lihong, Zhang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423609/
https://www.ncbi.nlm.nih.gov/pubmed/30816482
http://dx.doi.org/10.3892/mmr.2019.9986
Descripción
Sumario:Hepatic fibrosis is characterized by the aberrant production and deposition of extracellular matrix (ECM) proteins. Growing evidence indicates that the epithelial-mesenchymal transition serves a crucial role in the progression of liver fibrogenesis. Although a subset of microRNAs (miRNAs or miRs) has recently been identified as essential regulators of the EMT gene expression, studies of the EMT in hyperglycemic-induced liver fibrosis are limited. In the current study, it was observed that high glucose-treated AML12 cells occurred EMT process, and miR-32 expression was markedly increased in the liver tissue of streptozotocin-induced diabetic rats and in high glucose-treated AML12 cells. Additionally, the contribution of the EMT to liver fibrosis by targeting metastasis-associated gene 3 (MTA3) under hyperglycemic conditions was suppressed by AMO-32. The results indicated that miR-32 and MTA3 may be considered as novel drug targets in the prevention and treatment of liver fibrosis under hyperglycemic conditions. These finding improves the understanding of the progression of liver fibrogenesis.